FOURTH QUARTER (OCTOBER -
- Order intake
SEK 317.7 M (514.4) -
Net sales
SEK 299.6 M (264.4) -
Operating profit
SEK 44.4 M (20.7) -
Profit after tax
SEK 31.5 M (14.1) -
Earnings per share before/after dilution
SEK 0.92 (0.41) -
Cash flow
SEK 45.5 M (42.8) -
Order backlog
SEK 1,864.4 M (1,940.1) at the end of the period
TWELVE MONTHS (JANUARY -
- Order intake
SEK 1,004.2 M (1,218.5) -
Net sales
SEK 1,022.2 M (843.6) -
Operating profit
SEK 114.9 M (42.7) -
Profit after tax
SEK 81.6 M (23.8) -
Earnings per share before/after dilution
SEK 2.38 (0.69) -
Cash flow
SEK 190.3 M (46.8) -
The Board of Directors proposes an ordinary dividend of
SEK 0.70 (0) per share which corresponds to 30 percent of the group profit for the period in accordance with the dividend policy. Additionally, the Board of Directors proposes an extra dividend ofSEK 1.30 (0) per share.
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER
RaySearch secured an order fromIsrael -based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.Paul Scherrer Institute inSwitzerland placed an order for RayStation.The Mass General Cancer Center in the US placed an order and thereby expanded its installation of RayStation to also include proton treatment planning.Vejle Hospital inDenmark became the first center in the world to use RayStation for an online adaptive treatment with augmented CBCT.-
The hospital chain
Froedtert & Medical College of Wisconsin , US, placed an order for RayStation.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- The number of radiation therapy centers that have chosen RayStation for treatment planning now exceeds 1,000.
-
The Royal Marsden in the
UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis fromRaySearch . RaySearch acquired the product DrugLog from Pharmacolog.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO Telephone: +46 (0)8 510 530 00, johan.lof@raysearchlabs.com
The information contained in this interim report is such that
WEBCAST
CEO
Link to webcast:
You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
US: +1 (1) 631 570 56 13
About
* Subject to regulatory clearance in some markets.
https://news.cision.com/raysearch-laboratories/r/year-end-report-2023,c3934375
https://mb.cision.com/Main/1102/3934375/2623634.pdf
(c) 2024 Cision. All rights reserved., source